Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The scientific objective of the project is to evaluate if the topical administration of
Fluoresceinisothiocyanate (FITC)-Adalimumab during the endomicroscopic examination of the gut
in Crohn's disease (CD) patients shows an acceptable safety profile. Another objective is to
explore whether the use of FITC-Adalimumab as a predictive biomarker might reliably predict
patient response to Adalimumab therapy and hence enable optimized utilization of this
treatment option.